J&J's Zytiga, Xarelto to get spotlight for first-quarter results
This article was originally published in Scrip
Executive Summary
Johnson & Johnson’s drug business has been on a roll, garnering an important US approval and label expansions in the past several months while benefiting from rising sales of prostate cancer drug Zytiga and blood thinner Xarelto. That’s good since the company’s other businesses, medical devices and consumer products, are struggling.